Business
Shareholder Circular and Notice of General Meeting
Shareholder Circular and Notice of General Meeting.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 2663B OptiBiotix Health PLC 08 January 2018 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nShareholder Circular and Notice of General Meeting\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that, further to the announcement dated 28 November 2017, it has today posted a circular to shareholders seeking approval to undertake a capital reduction. The circular will shortly be available on the Company's website (www.optibiotix.com) and an extract of the circular appears below. \n \nThe General Meeting will be held at 11.00 a.m. on 25 January 2018 at the offices of Jeffreys Henry LLP, Finsgate, 5-7 Cranwood Street, London, EC1V 9EE.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n \nFor further information, please contact:\n \n\n\n\n\nOptiBiotix Health plc\n\n\nwww.optibiotix.com\n\n\n\n\nStephen O'Hara, Chief Executive\n\n\nContact via Walbrook below\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP\n\n\nTel: 020 7213 0880\n\n\n\n\nLiam Murray / Jo Turner\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap Broker\n\n\nTel: 020 7220 0500\n\n\n\n\nAdrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)\n\n\n\n\n\n\n\nTony Quirke (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n Mob: 07876 741 001\n\n\n\n\n\n\n\n\n\n \nAbout OptiBiotix - www.optibiotix.com \nOptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. \n \nThe aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. \n \nOptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and ...